Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Actovegin in Post-stroke Cognitive Impairment (PSCI)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Main Inclusion Criteria:~* Participant has suffered a recent supra-tentorial ischaemic stroke supported by computed tomography (CT) scan or magnetic resonance imaging (MRI) findings (in accordance with local practice).~* Participant is male or female, aged 60 years or above.~* Participant has a score on the National Institute of Health Stroke Scale (NIHSS) between 3 and 18 (inclusive).~* Participant is capable of completing the Montreal Cognitive Assessment (MoCA) and has a score of ≤ 25 points with adjustment for level of education (4-9 school years ≤ 23 points, 10-12 years ≤ 24 points, \>12 years ≤ 25 points).~Main Exclusion Criteria:~* Participant has a medical history of dementia.~* Participant has a known medical history of major depression or psychotic disorder.~* Participant is indicated for treatment with thrombolytics or carotid surgery as the current standard of care.~Randomisation Criteria:~* Inclusion Criteria.~* Ability to perform Alzheimer's Disease Assessment Scale + Cognitive Subscale Extended Version (ADAS-cog+).~* Exclusion Criteria.~* Clinically there is suspicion of progressive stroke.

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Actovegin (Type: ACTIVE_COMPARATOR): Actovegin 2000 mg solution, intravenous (IV) infusion for up to 20 days followed by 2 actovegin 200 mg, tablets, orally, 3 times a day for up to 6 months.
- Placebo (Type: PLACEBO_COMPARATOR): Actovegin placebo-matching solution, intravenous (IV) infusion for up to 20 days followed by 2 actovegin placebo-matching, tablets, orally, 3 times a day for up to 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).